Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Catheter Precision Inc (NYSE American: VTAK) announces Q4 and FY23 Results and Authorizes CEO to Make “Open Market” Purchases of Company Shares By: AB Newswire January 16, 2024 at 16:54 PM EST Catheter Precision Inc. (NYSE American: VTAK), an innovative medical device firm focused on enhancing outcomes for individuals with cardiac arrhythmias, is gaining attention following recent developments. On January 11, 2023, the company revealed that its Chairman and CEO, David Jenkins, has been granted approval to acquire up to 500,000 shares of Catheter Precision through open market transactions. This announcement positions the company as one to closely monitor in the coming days. The transactions are expected to occur across multiple trading days. Jenkins also commented on this development, emphasizing that his decision to invest more personally in the company reflects his confidence in Catheter Precision and its team. He highlighted the company's proactive efforts to enhance the treatment of cardiac arrhythmias, specifically mentioning the positive reception of the LockeT product by physicians and hospitals in its initial stages after receiving registration from the United States Food and Drug Administration. Simultaneously, Catheter Precision revealed its preliminary unaudited financial results for the fourth quarter and the entire fiscal year of 2023. The company disclosed that it achieved revenues for the quarter and fiscal year ending on December 21, 2023, respectively. As of the period's conclusion, Catheter Precision reported a cash balance of $3.6 million, with total assets under its control amounting to $30.7 million. Nevertheless, it's important to highlight that the provided figure is subject to potential adjustments. In addition, Catheter Precision reported a preliminary net loss of $2.5 million for the quarter and $72.4 million for the entire fiscal year. It was emphasized that the fiscal year's net losses incorporated a one-time write-off of $61 million associated with the impairment of goodwill. On Friday, January 12, 2024, Catheter Precision Inc. (NYSE American: VTAK) experienced a slight decrease in its closing, accompanied by lower-than-normal volume. The trading pattern revealed a hammer candlestick and exhibited several bullish indicators, such as trading in oversold territory. The Hammer, identified as a bullish reversal pattern, suggests a potential trend reversal, and can also signify bottoms or support levels. It is advisable to closely monitor this stock for the potential manifestation of these signals in the near future. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Catheter Precision Inc (NYSE American: VTAK) announces Q4 and FY23 Results and Authorizes CEO to Make “Open Market” Purchases of Company Shares By: AB Newswire January 16, 2024 at 16:54 PM EST Catheter Precision Inc. (NYSE American: VTAK), an innovative medical device firm focused on enhancing outcomes for individuals with cardiac arrhythmias, is gaining attention following recent developments. On January 11, 2023, the company revealed that its Chairman and CEO, David Jenkins, has been granted approval to acquire up to 500,000 shares of Catheter Precision through open market transactions. This announcement positions the company as one to closely monitor in the coming days. The transactions are expected to occur across multiple trading days. Jenkins also commented on this development, emphasizing that his decision to invest more personally in the company reflects his confidence in Catheter Precision and its team. He highlighted the company's proactive efforts to enhance the treatment of cardiac arrhythmias, specifically mentioning the positive reception of the LockeT product by physicians and hospitals in its initial stages after receiving registration from the United States Food and Drug Administration. Simultaneously, Catheter Precision revealed its preliminary unaudited financial results for the fourth quarter and the entire fiscal year of 2023. The company disclosed that it achieved revenues for the quarter and fiscal year ending on December 21, 2023, respectively. As of the period's conclusion, Catheter Precision reported a cash balance of $3.6 million, with total assets under its control amounting to $30.7 million. Nevertheless, it's important to highlight that the provided figure is subject to potential adjustments. In addition, Catheter Precision reported a preliminary net loss of $2.5 million for the quarter and $72.4 million for the entire fiscal year. It was emphasized that the fiscal year's net losses incorporated a one-time write-off of $61 million associated with the impairment of goodwill. On Friday, January 12, 2024, Catheter Precision Inc. (NYSE American: VTAK) experienced a slight decrease in its closing, accompanied by lower-than-normal volume. The trading pattern revealed a hammer candlestick and exhibited several bullish indicators, such as trading in oversold territory. The Hammer, identified as a bullish reversal pattern, suggests a potential trend reversal, and can also signify bottoms or support levels. It is advisable to closely monitor this stock for the potential manifestation of these signals in the near future. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
Catheter Precision Inc. (NYSE American: VTAK), an innovative medical device firm focused on enhancing outcomes for individuals with cardiac arrhythmias, is gaining attention following recent developments. On January 11, 2023, the company revealed that its Chairman and CEO, David Jenkins, has been granted approval to acquire up to 500,000 shares of Catheter Precision through open market transactions. This announcement positions the company as one to closely monitor in the coming days. The transactions are expected to occur across multiple trading days. Jenkins also commented on this development, emphasizing that his decision to invest more personally in the company reflects his confidence in Catheter Precision and its team. He highlighted the company's proactive efforts to enhance the treatment of cardiac arrhythmias, specifically mentioning the positive reception of the LockeT product by physicians and hospitals in its initial stages after receiving registration from the United States Food and Drug Administration. Simultaneously, Catheter Precision revealed its preliminary unaudited financial results for the fourth quarter and the entire fiscal year of 2023. The company disclosed that it achieved revenues for the quarter and fiscal year ending on December 21, 2023, respectively. As of the period's conclusion, Catheter Precision reported a cash balance of $3.6 million, with total assets under its control amounting to $30.7 million. Nevertheless, it's important to highlight that the provided figure is subject to potential adjustments. In addition, Catheter Precision reported a preliminary net loss of $2.5 million for the quarter and $72.4 million for the entire fiscal year. It was emphasized that the fiscal year's net losses incorporated a one-time write-off of $61 million associated with the impairment of goodwill. On Friday, January 12, 2024, Catheter Precision Inc. (NYSE American: VTAK) experienced a slight decrease in its closing, accompanied by lower-than-normal volume. The trading pattern revealed a hammer candlestick and exhibited several bullish indicators, such as trading in oversold territory. The Hammer, identified as a bullish reversal pattern, suggests a potential trend reversal, and can also signify bottoms or support levels. It is advisable to closely monitor this stock for the potential manifestation of these signals in the near future. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com